Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial-Reference-Cited by-同舟云学术

Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

Published:2012-07-27 Issue:8 Volume:64 Page:2504-2517
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Kavanaugh Arthur,van der Heijde Désirée,McInnes Iain B.,Mease Philip,Krueger Gerald G.,Gladman Dafna D.,Gómez-Reino Juan,Papp Kim,Baratelle Anna,Xu Weichun,Mudivarthy Surekha,Mack Michael,Rahman Mahboob U.,Xu Zhenhua,Zrubek Julie,Beutler Anna

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.34436/fullpdf

Reference23 articles.

1. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study;Kay;Arthritis Rheum,2008

2. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis;Emery;Arthritis Rheum,2009

3. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study;Keystone;Ann Rheum Dis,2009

4. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial;Inman;Arthritis Rheum,2008

5. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial;Smolen;Lancet,2009

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection;Cureus;2024-09-03

2. Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies;Expert Review of Clinical Immunology;2024-07-29

3. Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response;Scandinavian Journal of Rheumatology;2024-05-21

4. Pan American League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis;The Journal of Rheumatology;2024-04-01

5. Residual Disease Activity in Canadian Patients With Psoriatic Arthritis Treated With Advanced Therapies: Results From a Multiregistry Analysis (UNISON-PsA);The Journal of Rheumatology;2024-02-15